Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

LYL273

Cell therapy (CAR-T) · Kills target cells, directed at guanylyl cyclase C (GUCY2C) and CD19 · developed by Lyell Immunopharma

Phase 1/2 Most advanced trial

LYEL Developer

1 Registered trials

What is LYL273?

LYL273 is an autologous CAR T-cell therapy engineered to express a chimeric antigen receptor targeting guanylyl cyclase C (GCC), with CD19-specific CAR T-cells providing costimulation. The therapy is designed to recognize and kill GCC-expressing tumor cells. It is being studied in colorectal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (CAR-T)
Targets: guanylyl cyclase C (GUCY2C) (antigen), CD19 (antigen)
Mechanism: Kills target cells, directed at guanylyl cyclase C (GUCY2C) and CD19
Pathways: cytokine release, T-cell proliferation
Therapy area: Oncology
Developer: Lyell Immunopharma, Inc. (LYEL)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05319314	Phase 1/2	Colorectal Cancer	Recruiting	LYEL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal Cancer

Other drugs acting on GUCY2C / CD19

Blinatumomab FDA approved Inebilizumab FDA approved Linaclotide FDA approved Loncastuximab tesirine FDA approved Plecanatide FDA approved Budoprutug Phase 1/2 MK-1045 Phase 2/3

More from Lyell Immunopharma

IMPT-514 Phase 1/2 LYL797 Phase 1 LYL845 Phase 1 Rondecabtagene Autoleucel Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the LYEL page.

Follow LYEL, the company behind LYL273

See LYEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LYEL catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z